The BCG report, titled 'Trade in Transition: How to Prepare for a Patchwork World Order', explores the future of global trade, identifying four possible scenarios. The predominant scenario, 'multinodal trade mosaic', suggests that trade flows will concentrate around four main hubs: the United States, China, Plurilateralists, and BRICS+ without China. It is estimated that the share of the US in global trade will decrease, while China will continue to grow, with a compound annual growth rate of 5.5% with BRICS+.
Plurilateralists, a diverse group of advanced and emerging economies, will experience above-average trade growth due to their commitment to rules-based trade. Additionally, trade between BRICS+ without China and the rest of the world will increase, highlighting a reorganization of global trade relations. BCG emphasizes that leaders who integrate geopolitics into their strategies will have the best chances of success in this dynamic landscape.
Plurilateralists, a diverse group of advanced and emerging economies, will experience above-average trade growth due to their commitment to rules-based trade. Additionally, trade between BRICS+ without China and the rest of the world will increase, highlighting a reorganization of global trade relations. BCG emphasizes that leaders who integrate geopolitics into their strategies will have the best chances of success in this dynamic landscape.
Sources
Latest News
08:06
The U.S. Treasury debt has reached $40.047 trillion, exceeding CBO estimates. The rapid increase in the deficit raises concerns in the financial markets.
07:59
The Washington Post: Russians withdraw billions from banks, fearing that Putin will confiscate their deposits to finance his war
07:46
Hungary: The construction of a riverbed threshold on the Danube has raised the water level by 15-20 cm, preventing the shutdown of the turbines at the Paks nuclear power plant.
07:45
Kiev was the target of a new attack with Russian ballistic missiles. At least six people have died and 12 have been injured.
07:37
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
See more news